Showing results (491-500 of 525) with videos related to
Sort By:
Pageof 53
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.Cell Reports|May 14, 2020
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV ChallengeBarbara K Felber, Zhongyan Lu, Xintao Hu, et al.Cell Host & Microbe|September 11, 2015
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesM Anthony Moody, Feng Gao, Thaddeus C Gurley, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.Proceedings of the National Academy of Sciences of the United States of America|May 21, 2008
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionBrandon F Keele, Elena E Giorgi, Jesus F Salazar-Gonzalez, et al.The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.Plos Pathogens|October 8, 2011
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsS Gnanakaran, Tanmoy Bhattacharya, Marcus Daniels, et al.Cell Reports|April 4, 2025
A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike proteinSharon L Schendel, Xiaoying Yu, Peter J Halfmann, et al.Pageof 53